Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Randomized Double-Blind, Placebo-Controlled Study of Therapeutic Effects of Silymarin in Β-Thalassemia Major Patients Receiving Desferrioxamine Publisher Pubmed



Moayedi B1 ; Gharagozloo M1 ; Esmaeil N1 ; Maracy MR2 ; Hoorfar H3 ; Jalaeikar M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Division of Thalassemia and Hemophilia, Seyed-al-shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Source: European Journal of Haematology Published:2013


Abstract

Thalassemia is one of the most common genetic disorders worldwide. Chronic blood transfusions treat the underlying anemia but may lead to iron toxicity. Effective iron chelation remains one of the main targets of clinical management of thalassemia major. In this study, iron-chelating activity of silymarin, a flavonolignan isolated from silybum marianum, was examined in β-thalassemia major. Methods: Patients were treated with the combination of desferrioxamine and silymarin (Legalon®; n = 49) or desferrioxamine plus placebo (n = 48) for 9 months. The serum levels of ferritin, iron, total iron-binding capacity (TIBC), soluble transferrin receptor, and hepcidin were determined at the baseline and after 9-month therapy. Liver function test was performed before and after treatment in both groups. Results: Serum ferritin levels decreased significantly from the beginning to the end of silymarin treatment (3028.8 ± 2002.6 vs. 1972.2 ± 1250.6 ng/mL); however, no significant change in serum ferritin was observed in the patients receiving placebo (2249.0 ± 1304.2 vs. 2015.6 ± 1146.8). Moreover, serum iron and TIBC levels were significantly reduced in silymarin group compared with placebo. Patients on silymarin therapy also exhibited a significant decrease in serum levels of hepcidin and soluble transferrin receptor after 9-month treatment period. A significant improvement in liver function test was observed in silymarin group in comparison with placebo. Conclusion: This study shows that silymarin is effective at reducing iron overload in patients when used in conjunction with desferrioxamine. Therapeutic effects of silymarin on a background of desferrioxamine suggest the potential effectiveness of silymarin alone in reducing body iron burden. © 2012 John Wiley & Sons A/S.
Related Docs
View other Related Docs
1. Combined Therapy of Silymarin and Desferrioxamine in Patients With Β-Thalassemia Major: A Randomized Double-Blind Clinical Trial, Fundamental and Clinical Pharmacology (2009)
2. Evaluating the Safety and Efficacy of Silymarin in Β-Thalassemia Patients: A Review, Hemoglobin (2015)
3. Immunomodulatory Effects of Silymarin in Patients With Β-Thalassemia Major, International Immunopharmacology (2013)
4. Serum Levels of Tgfβ, Il-10, Il-17, and Il-23 Cytokines in Β-Thalassemia Major Patients: The Impact of Silymarin Therapy, Immunopharmacology and Immunotoxicology (2014)
5. Therapeutic Effects of Deferoxamine and Silymarin Versus Deferoxamine Alone in Β-Thalassemia Major Based on Findings of Liver Mri, Journal of Research in Medical Sciences (2012)
6. Co-Administration of Silymarin and Deferoxamine Against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model, International Journal of Preventive Medicine (2014)
7. Evaluation of Iron Status by Serum Ferritin Level in Iranian Carriers of Beta Thalassemia Minor, International Journal for Vitamin and Nutrition Research (2008)
8. Efficacy and Safety of Iranian Made Deferasirox (Osveral®)In Iranian Major Thalassemic Patients With Transfusional Iron Overload: A One Year Prospective Multicentric Open-Label Non-Comparative Study, DARU, Journal of Pharmaceutical Sciences (2011)
Experts (# of related papers)
View all Related Experts
Nafiseh Esmaeil (3)
Nahid Eskandari (3)
Other Related Docs
9. Effects of Silymarin on the Proliferation and Glutathione Levels of Peripheral Blood Mononuclear Cells From Β-Thalassemia Major Patients, International Immunopharmacology (2006)
10. The Influence of Iron Loading and Iron Chelation on the Proliferation and Telomerase Activity of Human Peripheral Blood Mononuclear Cells, Iranian Journal of Immunology (2009)
11. Review on Iron and Its Importance for Human Health, Journal of Research in Medical Sciences (2014)
12. Silymarin Impacts on Immune System As an Immunomodulator: One Key for Many Locks, International Immunopharmacology (2017)
13. Protective Role of Silymarin and Deferoxamine Against Iron Dextran-Induced Renal Iron Deposition in Male Rats, International Journal of Preventive Medicine (2013)
14. The Effects of Silymarin Consumption on Inflammation and Oxidative Stress in Adults: A Systematic Review and Meta-Analysis, Inflammopharmacology (2024)
15. The Correlation Between the Cardiac and Hepatic Iron-Overload in Patients With Thalassemia Major Who Received Multiple Transfusion, Journal of Isfahan Medical School (2010)
16. The Effect of Combination Iron Chelating Agents on Reducing the Severity Grading of Heart and Liver Iron Overload in Β-Thalassemia Patients, Iranian Journal of Pediatric Hematology and Oncology (2019)
17. Double-Faced Cell-Mediated Immunity in Β-Thalassemia Major: Stimulated Phenotype Versus Suppressed Activity, Annals of Hematology (2009)
18. An Evaluation of Sensory Neural Hearing Loss in Thalassaemic Patients Treated With Desferrioxamine and Its Risk Factors, Journal of Research in Medical Sciences (2005)
19. Association Between Neutrophil Geletinase-Associated Lipocalin and Iron Deficiency Anemia in Children on Chronic Dialysis, Journal of Research in Medical Sciences (2014)
20. Beneficial Effects of the Treatment of Iron Deficiency on Clinical Condition, Left Ventricular Function, and Quality of Life in Patients With Chronic Heart Failure, Acta Biomedica (2018)
21. The Relation Between Body Iron Store and Ferritin, and Coronary Artery Disease, ARYA Atherosclerosis (2014)
22. T2-Weighted Cardiovascular Magnetic Resonance and Echocardiographic Arterial Elasticity Criteria for Monitoring Cardiac Siderosis in Patients With Beta-Thalassemia Major, Journal of Research in Medical Sciences (2022)
23. Momelotinib in Myelofibrosis and Beyond: A Comprehensive Review of Therapeutic Insights in Hematologic Malignancies, Discover Oncology (2024)
24. The Effects of Herbal Medicines on Cancer Therapy-Induced Oral Mucositis: A Literature Review, Phytotherapy Research (2022)
25. Effectiveness of Twice Weekly Iron Supplementation Compared With Daily Regimen in Reducing Anemia and Iron Deficiency During Pregnancy: A Randomized Trial in Iran, Journal of Research in Medical Sciences (2008)
26. Inhibition of Apoptosis and Proliferation in T Cells by Immunosuppressive Silymarine, Iranian Journal of Allergy, Asthma and Immunology (2017)
27. Assessment of the Relationship Between Iron Overload Based on Cardiac T2* Mri and Fragmented Qrs in Beta-Thalassemia Major Patients, Shiraz E Medical Journal (2020)
28. Treatment of Chemotherapy Induced Anemia; a Randomized Clinical Trial to Compare Quality of Life in Patients Taking Intravenous Versus Oral Iron, Immunopathologia Persa (2021)
29. Cardiomyopathy in Thalassemia: Quick Review From Cellular Aspects to Diagnosis and Current Treatments, Lab Medicine (2020)
30. Globin Gene Mutations in Isfahan Province, Iran, Hemoglobin (2014)
31. Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, in Patients With Β-Thalassemia Major, Hemoglobin (2013)
32. Evaluation of the Prevalence and Determinants of Iron Deficiency Anemia in a Sample of Preschool-Aged Children in Isfahan City, Iran, Journal of Isfahan Medical School (2017)
33. The Effect of Chromium on Parameters Related to Iron Metabolism, Biological Trace Element Research (1992)
34. Hypercoagulopathy and Serum “Natural Antithrombotic Factors” in Beta-Thalassemia Major, Journal of Isfahan Medical School (2008)
35. The Effect of Silymarin on the Expression of Chemokine Receptors in T Helper 1 (Th1) Cells, Journal of Isfahan Medical School (2014)
36. Effects of Silybum Marianum on Patients With Chronic Hepatitis C, Journal of Research in Medical Sciences (2011)
37. The Comparison of Efficacy of Original Brand Deferoxamine With Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients With Thalassemia Major, Iranian Journal of Blood and Cancer (2018)
38. Comparison of Iron Chelation Effects of Deferoxamine, Deferasirox, and Combination of Deferoxamine and Deferiprone on Liver and Cardiac T2* Mri in Thalassemia Maior, Caspian Journal of Internal Medicine (2017)
39. The Effect of Silymarin on the Proliferating of the Activated Human T Cells in Vitro, Journal of Isfahan Medical School (2014)
40. The Effects of Silymarin Supplementation on Metabolic Status and Oxidative Stress in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Clinical Trials, Complementary Therapies in Medicine (2018)
41. The Effect of Simultaneous Administration of Zinc Sulfate and Ferrous Sulfate in the Treatment of Anemic Pregnant Women, Journal of Research in Medical Sciences (2005)
42. The Hepatorenal Protective Effects of Silymarin in Cancer Patients Receiving Chemotherapy: A Randomized, Placebo-Controlled Trial, BMC Complementary Medicine and Therapies (2024)
43. Association of Body Mass Index and Serum Ferritin Level in Pediatrics With Beta-Thalassemia Major Disease, Iranian Journal of Pediatric Hematology and Oncology (2022)
44. Effects of Lactulose and Silymarin on Liver Enzymes in Cirrhotic Rats, Canadian Journal of Physiology and Pharmacology (2017)
45. Preventive Effect of Novel Nanomissile of Silymarin on Liver Injury Induced by Carbon Tetrachloride in Rat, Scientific Journal of Kurdistan University of Medical Sciences (2021)
46. Effects of Iron on Vitamin D Metabolism: A Systematic Review, International Journal of Preventive Medicine (2016)
47. Quercetin Attenuates Neurotoxicity Induced by Iron Oxide Nanoparticles, Journal of Nanobiotechnology (2021)